Tuesday’s Midday Stock Update: ImmunoCellular Therapeutics (IMUC), Orexigen (OREX), Anthera Pharmaceuticals (ANTH), IntelliPharmaCeutics International (IPCI), Nordic American Tanker (NAT)

By Carrie Williams

So far Tuesday, November 27, NASDAQ is up 1.06% and the S&P is up 1.08%. Here are this morning’s most active stocks: ImmunoCellular Therapeutics (IMUCResearch Report), Orexigen (OREXResearch Report), Anthera Pharmaceuticals (ANTHResearch Report), IntelliPharmaCeutics International (IPCIResearch Report) and Nordic American Tanker (NATResearch Report).

ImmunoCellular Therapeutics is up 54.76% in midday trading to $0.03. Shares opened today at $0.02. The company has a 52-week low of $0.02 and a 52-week high of $0.00.

Orexigen is up 40.62% in midday trading to $0.00. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00. In the last 30 days, insiders have sold $15.46K worth of OREX shares. Over the last 3 months, the insider sentiment on Orexigen has been negative based on 3 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Anthera Pharmaceuticals is up 37.5% in midday trading to $0.05. Shares opened today at $0.04. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

IntelliPharmaCeutics International is down -13.73% in midday trading to $0.44. Shares opened today at $0.51. The company has a 52-week low of $0.35 and a 52-week high of $0.00.

Nordic American Tanker is up 11.42% in midday trading to $3.12. Shares opened today at $2.80. The company has a 52-week low of $1.82 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $2.75, marking a -1.79% potential downside from current levels. In a report issued on November 12, Seaport Global analyst Magnus Fyhr maintained a Hold rating on NAT, with a price target of $3, which implies an upside of 7% from current levels. Separately, on the same day, Maxim Group’s James Jang maintained a Sell rating on the stock and has a price target of $1.

Trending Stocks Based on Insider Activity >>